@article{ca6ce027bd52467c86589e0938ca48be,
title = "Associations between serum albumin and serious non-AIDS events among people living with HIV",
abstract = "Objective: Lower serum albumin (sAlb) has been associated with an increased risk of mortality and AIDS among people living with HIV and may be associated with the development of serious non-AIDS events (SNAEs). We evaluated the long-term association between sAlb and the risk of SNAEs. Design: Prospective multinational cohort study. Methods: D:A:D participants without SNAEs were followed from first routine sAlb value to the first of a new SNAE [cardiovascular disease (CVD), end-stage liver disease (ESLD), end-stage renal disease (ESRD), non-AIDS malignancy (NADM), death from non-AIDS cause], AIDS-death, 6 months after last visit or 1 February 2016. Poisson regression was used to determine associations between sAlb and a new SNAE, CVD, or NADM event, with adjustment for potential confounders. Models additionally tested whether the associations were modified by age, follow-up time, smoking status, CD4 and viral load. Results: Of 16 350 participants (71.8% male, median age 44 years), 1463 developed an SNAE (371 CVD, 200 ESLD, 40 ESRD, 553 NADM, 299 deaths from other non-AIDS causes) over 80 264 person-years. Increased sAlb was associated with a decreased risk of an SNAE [adjusted rate ratio per 5 g/l: SNAE 0.79 (95% confidence interval: 0.76, 0.83); CVD 0.87 (0.80, 0.94); NADM 0.88 (0.82, 0.95)]. The association did not appear to wane with additional years of follow-up (P-interaction = 0.79) but was stronger for current smokers than for never smokers (P-interaction ",
keywords = "Albumin, Biomarker, Cancer, Cardiovascular disease, Non-AIDS comorbidity, Smoking, CD4 antigen, serum albumin, human serum albumin, adult, age, albumin blood level, Article, cardiovascular disease, cohort analysis, end stage liver disease, end stage renal disease, female, follow up, human, Human immunodeficiency virus infected patient, Human immunodeficiency virus infection, major clinical study, male, multicenter study, priority journal, prospective study, serious non aids event, smoking, virus load, chronic kidney failure, clinical trial, complication, neoplasm, risk assessment, survival analysis, Adult, Cardiovascular Diseases, End Stage Liver Disease, Female, Follow-Up Studies, HIV Infections, Humans, Kidney Failure, Chronic, Male, Neoplasms, Prospective Studies, Risk Assessment, Serum Albumin, Human, Survival Analysis",
author = "A. Ronit and C.I. Hatleberg and L. Ryom and F. Bonnet and W. El-Sadr and P. Reiss and R. Weber and C. Pradier and {De Wit}, S. and M. Law and {D'Arminio Monforte}, A. and J. Lundgren and A. Mocroft and A.N. Phillips and C.A. Sabin and Ferran Torres",
note = "Cited By :3 Export Date: 17 February 2022 CODEN: AIDSE Correspondence Address: Ronit, A.; Department of Infectious Diseases, Blegdamsvej 9, Denmark Chemicals/CAS: serum albumin, 9048-46-8; human serum albumin, 9048-49-1; Serum Albumin, Human Funding details: 260694 Funding details: National Institutes of Health, NIH Funding details: U.S. Food and Drug Administration, FDA Funding details: National Institute of Allergy and Infectious Diseases, NIAID, U01-AI069907 Funding details: Bristol-Myers Squibb, BMS Funding details: Pfizer, 148522 Funding details: GlaxoSmithKline, GSK Funding details: Janssen Research and Development, JRD Funding details: Gilead Sciences Funding details: AbbVie Funding details: Boehringer Ingelheim Funding details: Janssen Pharmaceuticals Funding details: Merck Sharp and Dohme, MSD Funding details: ViiV Healthcare Funding details: Cilag Funding details: Schweizerischer Nationalfonds zur F{\"o}rderung der Wissenschaftlichen Forschung, SNF, 108787 Funding details: Danmarks Grundforskningsfond, DNRF Funding details: University of New South Wales, UNSW Funding details: Ministerie van Volksgezondheid, Welzijn en Sport, VWS Funding details: Agence Nationale de Recherches sur le Sida et les H{\'e}patites Virales, ANRS Funding details: Fundaci{\'o}n Emilio Soldevilla para la Investigaci{\'o}n y el Desarrollo en Econom{\'i}a de la Empresa, FESIDE, 5U01AI042170–10, 5U01AI046362-03, FIPSE 3171/00 Funding details: INCLIVA Instituto de Investigaci{\'o}n Sanitaria, FIS 99/0887 Funding text 1: Declaration of interests: A.R., C.I.H., L.R., F.B., W.E.S., R.W., S.d.W., J.D.L., and A.N.P. have no disclosures to declare. Through his institution, P.R. has through his institution received independent scientific grant support from Gilead Sciences, Janssen Pharmaceutical Inc., Merck & Co, Bristol-Myers Squibb and ViiV HealthCare; he has served on scientific advisory board for Gilead Sciences and a data safety monitoring committee for Janssen Pharmaceuticals Inc.; he chaired a scientific symposium by ViiV HealthCare, for which his institution has received remuneration. C.P. reports nonfinancial support from Janssen, personal fees from Gilead Sciences, nonfinancial support from ViiV HealthCare and nonfinancial support from MSD. M.L. has received unrestricted grants from Boehringer Ingelheim, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag and ViiV HealthCare; he also received consultancy payments from Gilead Sciences, and DSMB sitting fees from Sirtex Pty Ltd. A.d{\textquoteright}A.M. has received grants for advisory boards or lectures by Abbve, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD and ViiV HealthCare. A.M. has received travel support, honoraria, speaker fees and/or lecture fees from Bristol-Myers Squibb, Gilead Sciences, ViiV HealthCare, Pfizer, Merck, BI and Wragge LLC. C.S. has received funding for membership of Data Safety and Monitoring Boards, Advisory Boards, speaker panels and for preparation of educational materials from Gilead Sciences, ViiV HealthCare and Janssen-Cilag. Funding text 2: Financial support: The D:A:D study was supported by a grant (grant number DNRF126) from the Danish National Research Foundation (CHIP & PERSI-MUNE); the Highly Active Antiretroviral Therapy Oversight Committee (HAARTOC), a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc. and Janssen Pharmaceuticals. Supported also by a grant from the Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health and the Environment to Stiching HIV Monitoring (ATHENA); by a grant from the Agence nationale de recherches sur le sida et les h{\'e}patites virales (ANRS, Action Coordonn{\'e}e no. 7, Cohortes) to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the US National Institutes of Health{\textquoteright}s National Institute of Allergy and Infectious Diseases (NIAID) (grant number U01-AI069907) and by unconditional grants from Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim; Janssen-Cilag; ViiV Healthcare. The Kirby Institute is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales; by grants from the Fondo de Investigaci{\'o}n Sanitaria (grant number FIS 99/0887) and Fundaci{\'o}n para la Investigaci{\'o}n y la Prevenci{\'o}n del SIDA en Espan{\~a} (grant number FIPSE 3171/00), to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health [grants number 5U01AI042170–10, 5U01AI046362-03], to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by primary funding provided by the European Union{\textquoteright}s Seventh Framework Programme for research, technological development and demonstration under EuroCoord grant agreement no. 260694 and unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC [the participation of centers from Switzerland is supported by The Swiss National Science Foundation (grant 108787)] to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant #148522) and by the SHCS research foundation. References: Sabin, C.A., Griffioen, A., Yee, T.T., Emery, V.C., Herrero-Martinez, E., Phillips, A.N., Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: A longitudinal study (2002) Lancet, 360, pp. 1546-1551; Shah, S., Smith, C.J., Lampe, F., Youle, M., Johnson, M.A., Phillips, A.N., Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: Relationships with gender (2007) HIV Med, 8, pp. 38-45; Feldman, J.G., Burns, D.N., Gange, S.J., Bacchetti, P., Cohen, M., Anastos, K., Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV study (2000) AIDS, 14, pp. 863-870; Scherzer, R., Heymsfield, S.B., Rimland, D., Powderly, W.G., Tien, P.C., Bacchetti, P., Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection (2017) AIDS, 31, pp. 71-79; Lang, J., Scherzer, R., Weekley, C.C., Tien, P.C., Grunfeld, C., Shlipak, M.G., Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans (2013) AIDS, 27, pp. 1339-1343; Sudfeld, C.R., Isanaka, S., Aboud, S., Mugusi, F.M., Wang, M., Chalamilla, G.E., Association of serum albumin concentration with mortality, morbidity, CD4 T-cell reconstitution among Tanzanians initiating antiretroviral therapy (2013) J Infect Dis, 207, pp. 1370-1378; Ronit, A., Sharma, S., Baker, J.V., Mngqibisa, R., Delory, T., Caldeira, L., Serum albumin as a prognostic marker for serious non-AIDS endpoints in the Strategic timing of antiretroviral treatment (START) study (2017) J Infect Dis, 217, pp. 405-412; Dusingize, J.C., Hoover, D.R., Shi, Q., Mutimura, E., Kiefer, E., Cohen, M., Association of serum albumin with markers of nutritional status among HIV-infected and uninfected Rwandan women (2012) PLoS One, 7; Friedman, A.N., Fadem, S.Z., Reassessment of albumin as a nutritional marker in kidney disease (2010) J Am Soc Nephrol, 21, pp. 223-230; Levitt, D.G., Levitt, M.D., Human serum albumin homeostasis: A new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements (2016) Int J Gen Med, 9, pp. 229-255; Fleck, A., Raines, G., Hawker, F., Trotter, J., Wallace, P.I., Ledingham, I.M., Increased vascular permeability: A major cause of hypoalbuminaemia in disease and injury (1985) Lancet, 1, pp. 781-784; Heinrich, P.C., Castell, J.V., Andus, T., Interleukin-6 and the acute phase response (1990) Biochem J, 265, pp. 621-636; Neuhaus, J., Jacobs, D.R., Jr., Baker, J.V., Calmy, A., Duprez, D., La, R.A., Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection (2010) J Infect Dis, 201, pp. 1788-1795; Liu, X., Ye, L., Christianson, G.J., Yang, J.Q., Roopenian, D.C., Zhu, X., NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences (2007) J Immunol, 179, pp. 2999-3011; Chaudhury, C., Mehnaz, S., Robinson, J.M., Hayton, W.L., Pearl, D.K., Roopenian, D.C., The major histocompatibility complexrelated Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan (2003) J Exp Med, 197, pp. 315-322; Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., The extraordinary ligand binding properties of human serum albumin (2005) IUBMB Life, 57, pp. 787-796; Evans, T.W., Review article: Albumin as a drug: Biological effects of albumin unrelated to oncotic pressure (2002) Aliment Pharmacol Ther, 16, pp. 6-11; Shaper, A.G., Wannamethee, S.G., Whincup, P.H., Serum albumin and risk of stroke, coronary heart disease, and mortality: The role of cigarette smoking (2004) J Clin Epidemiol, 57, pp. 195-202; Nelson, J.J., Liao, D., Sharrett, A.R., Folsom, A.R., Chambless, L.E., Shahar, E., Serum albumin level as a predictor of incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study (2000) Am J Epidemiol, 151, pp. 468-477; Shiels, M.S., Katki, H.A., Freedman, N.D., Purdue, M.P., Wentzensen, N., Trabert, B., Cigarette smoking and variations in systemic immune and inflammation markers (2014) J Natl Cancer Inst, 106, p. dju294",
year = "2018",
month = aug,
doi = "10.1097/QAD.0000000000001900",
language = "English",
volume = "32",
pages = "1837--1848",
number = "13",
}
